A study showed that pretreatment with luzindole (a melatonin receptor antagonist targeting MT1 and MT2) did not prevent melatonin from enhancing thapsigargin‐induced CHOP expression in renal cancer cells, suggesting a potential receptor‐independent mechanism [68]. This evidence concerns the gene DDIT3 and renal carcinoma.